-
NextPharma Technologies Partners With CARBOGEN AMCIS In Alliance Which Combines Investigational Medicinal Product And Active Pharmaceutical Ingredient Services For Highly Potent Active Pharmaceutical Ingredients
10/8/2009
NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that it has entered into an agreement with CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, to provide customers with seamless development services covering highly potent pharmaceutical ingredient (APIs) and Investigational Medicinal Products (IMPs) for clinical trials.
-
West Dedicates Injection Molding Plant In China
10/1/2009
West Pharmaceutical Services, Inc., the global leader in innovative solutions for injectable drug administration, recently announced the formal opening of its injection molding factory in the Shanghai Qingpu Industrial Zone (SQIZ) in China.
-
Vical Licensee Sanofi-Aventis Completes Enrollment In Phase 3 Angiogenesis Trial
9/29/2009
Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects final data from this trial in late 2010.
-
Merck Receives Positive CHMP Opinion For JANUVIA (Sitagliptin) And JANUMET (Sitagliptin/Metformin) As Add-On To Insulin In The European Union
9/29/2009
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA tablets and JANUMET tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.
-
Haupt Pharma: New Separate Production Area For Sex Hormone-Containing Solids Sets Standards For EHS And GMP
9/29/2009
Handling of sex hormones as highly potent pharmacologically active substances requires increasingly complex facilities and machinery to protect the product, the workforce and the environment. Haupt Pharma meets these demands by continuously investing in modern technologies.
-
Deblistering Device Keeps Production Ahead Of Pack
9/24/2009
The increased need for pharmaceutical packaging companies to reduce waste and disposal costs in a way that minimises the impact on the environment has led to an increased demand for specialised deblistering machines according to Sepha.
-
Q Chip To Develop Biopharmaceutical Portfolio Based On Its Established Bioencapsulation Technology
9/24/2009
Q Chip, a biopharmaceutical drug delivery company, is developing a range of sustained-release biosimilars using its patented Q-Sphera™ bioencapsulation platform.
-
Vetter Opens Technologically Advanced Service Facility In The U.S., Strengthening Commitment To North American Market
9/24/2009
One of the world’s leading providers of aseptically pre-filled injection systems, Vetter will open Vetter Development Service (VDS), a technologically advanced customer service facility located in Chicago, allowing the company to provide greater commitment and support toward the product needs of its North American customers.
-
Edmund Optics Releases New Catalog With Biotech Focus
9/22/2009
Edmund Optics (EO), the premier provider of optical components, has released a catalog featuring product lines of specific interest for researchers and product developers working in the demanding biotech field.
-
New Advice On OTC Analgesics Containing Codeine
9/4/2009
The Medicines and Healthcare products Regulatory Agency (MHRA) recently announced new advice on over the counter (OTC) medicines containing codeine and dihydrocodeine (DHC) to minimise the risk of overuse and addiction.
